A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London.
A type-I collagen derivative with unique properties enables photolithographic bioprinting of 3-D scaffolds.
Slight changes to the system for allocating deceased-donor kidneys could result in higher rates of organ procurement and lead to more kidney transplants across the country, according to new research co-authored by an Indiana University Kelley School of Business professor.
New research from the University of Maryland School of Medicine suggests that the system for choosing transplant recipients in chronic obstructive pulmonary disease (COPD) may underestimate how long a person might survive without a lung transplant and therefore, may mislead clinicians.
New research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease, a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation.
Based on their analysis, the researchers suggest that changing how so-called lower quality kidneys are allocated geographically could result in anywhere from 58 additional to 174 additional kidney transplants per year to help more patients get off dialysis treatments and live more normal lives.
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of the cornea. The cornea is the eye's clear outer covering. Currently, donor corneas are generally not used for surgery in the United States if they have been preserved for longer than seven days.
Adoptive cell therapy for cancer involves harvesting T cells from a patient and expanding and sometimes modifying them in the laboratory before reinfusion. It has been challenging to create T cells that are both potent and durable. In a Cell Metabolism article, Medical University of South Carolina investigators report the potent anti-tumor properties of hybrid Th1/Th17 cells that combine the cancer-fighting properties of Th1 cells and the ability of Th17 cells to self-renew and regenerate.
A medical team at the Ruhr-Universität Bochum's burn unit and the Center for Regenerative Medicine at the University of Modena (Italy) were the first ever to successfully treat a child suffering from extensive skin damage using transplants derived from genetically modified stem cells. The boy is a so-called butterfly child: he suffers from epidermolysis bullosa, a genetic skin disease that had destroyed approximately 80 percent of his epidermis.
German scientists have developed a novel nuclear medicine test that can determine whether a kidney transplant patient has developed infection in the transplanted tissue. The study, which utilizes positron emission tomography/magnetic resonance imaging (PET/MRI), is presented in the November issue of The Journal of Nuclear Medicine.